PURPOSE: [(11)C]NNC 112 and [(11)C]SCH 23390 are selective positron emission tomography (PET) tracers for visualizing dopamine D(1) receptors. It is known that both have some affinity for serotonin 2A receptors, but previous studies have suggested this is negligible compared to D(1) affinity. We sought to verify this property in vivo. PROCEDURES: Two baboons were scanned to measure the selectivity of both tracers with a displacement paradigm. Four baboons were scanned to directly assess [(11)C] NNC 112 affinity for both receptors. RESULTS: In vivo, D(1) to 5-HT(2A) selectivity is six to fourteenfold, not 100-fold as previously reported by other investigators. CONCLUSION: We conclude that about 1/4 of the cortical signal of both [(11)C]NNC 112 and [(11)C]SCH 23390 is due to binding to 5-HT(2A) receptors. If confirmed in humans, this suggests caution should be exercised when drawing conclusions from studies using either tracer. These results also indicate the need for more selective tracers for the D(1) receptor.
PURPOSE: [(11)C]NNC 112 and [(11)C]SCH 23390 are selective positron emission tomography (PET) tracers for visualizing dopamine D(1) receptors. It is known that both have some affinity for serotonin 2A receptors, but previous studies have suggested this is negligible compared to D(1) affinity. We sought to verify this property in vivo. PROCEDURES: Two baboons were scanned to measure the selectivity of both tracers with a displacement paradigm. Four baboons were scanned to directly assess [(11)C] NNC 112 affinity for both receptors. RESULTS: In vivo, D(1) to 5-HT(2A) selectivity is six to fourteenfold, not 100-fold as previously reported by other investigators. CONCLUSION: We conclude that about 1/4 of the cortical signal of both [(11)C]NNC 112 and [(11)C]SCH 23390 is due to binding to 5-HT(2A) receptors. If confirmed in humans, this suggests caution should be exercised when drawing conclusions from studies using either tracer. These results also indicate the need for more selective tracers for the D(1) receptor.
Authors: R K Sunahara; H C Guan; B F O'Dowd; P Seeman; L G Laurier; G Ng; S R George; J Torchia; H H Van Tol; H B Niznik Journal: Nature Date: 1991-04-18 Impact factor: 49.962
Authors: J H Meador-Woodruff; S P Damask; J Wang; V Haroutunian; K L Davis; S J Watson Journal: Neuropsychopharmacology Date: 1996-07 Impact factor: 7.853
Authors: A Abi-Dargham; N Simpson; L Kegeles; R Parsey; D R Hwang; S Anjilvel; Y Zea-Ponce; I Lombardo; R Van Heertum; J J Mann; C Foged; C Halldin; M Laruelle Journal: Synapse Date: 1999-05 Impact factor: 2.562
Authors: David M Mottola; Jason D Kilts; Mechelle M Lewis; Hilary S Connery; Q David Walker; Sara R Jones; Raymond G Booth; Deborah K Hyslop; Monford Piercey; R Mark Wightman; Cindy P Lawler; David E Nichols; Richard B Mailman Journal: J Pharmacol Exp Ther Date: 2002-06 Impact factor: 4.030
Authors: F Borsini; E Giraldo; E Monferini; G Antonini; M Parenti; G Bietti; A Donetti Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 1995-09 Impact factor: 3.000
Authors: A O Laihinen; J O Rinne; H M Ruottinen; K A Någren; P K Lehikoinen; V J Oikonen; U H Ruotsalainen; U K Rinne Journal: J Nucl Med Date: 1994-12 Impact factor: 10.057
Authors: Chelsea L Robertson; Kenji Ishibashi; Mark A Mandelkern; Amira K Brown; Dara G Ghahremani; Fred Sabb; Robert Bilder; Tyrone Cannon; Jacqueline Borg; Edythe D London Journal: J Neurosci Date: 2015-04-15 Impact factor: 6.167
Authors: Eline M P Poels; Ragy R Girgis; Judy L Thompson; Mark Slifstein; Anissa Abi-Dargham Journal: Psychopharmacology (Berl) Date: 2013-03-05 Impact factor: 4.530
Authors: Scott J Moeller; Kyoji Okita; Chelsea L Robertson; Michael E Ballard; Anna B Konova; Rita Z Goldstein; Mark A Mandelkern; Edythe D London Journal: Neuropsychopharmacology Date: 2017-06-30 Impact factor: 7.853
Authors: Alexander K Converse; Colleen F Moore; James E Holden; Elizabeth O Ahlers; Jeffrey M Moirano; Julie A Larson; Leslie M Resch; Onofre T DeJesus; Todd E Barnhart; Robert J Nickles; Dhanabalan Murali; Bradley T Christian; Mary L Schneider Journal: Alcohol Clin Exp Res Date: 2014-12 Impact factor: 3.455
Authors: Mark Slifstein; Raymond F Suckow; Jonathan A Javitch; Thomas Cooper; Jeffrey Lieberman; Anissa Abi-Dargham Journal: J Cereb Blood Flow Metab Date: 2010-06-23 Impact factor: 6.200
Authors: Dara M Cannon; Jacqueline M Klaver; Summer A Peck; Denise Rallis-Voak; Kristine Erickson; Wayne C Drevets Journal: Neuropsychopharmacology Date: 2008-10-22 Impact factor: 7.853